Isovorin

Levoleucovorin, the active ingredient in Isovorin, is a folate analog presented as a sterile solution for intravenous and intramuscular use. It is employed as an antineoplastic adjuvant to support DNA synthesis and to enhance the efficacy of fluoropyrimidine chemotherapy, particularly in patients receiving high‑dose methotrexate or 5‑fluorouracil.

GNH USA supplies Isovorin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Isovorin is a folate analog used in oncology and metabolic support pathways. It provides reduced folate to improve treatment outcomes and address deficiency.

- Rescue therapy after high-dose methotrexate: supplies reduced folate to mitigate toxicity and support recovery. - Enhancement of 5‑fluorouracil chemotherapy: augments drug activity by stabilizing the active metabolite. - Folate deficiency: restores folate levels in patients with inadequate dietary intake or increased metabolic demand.

Levoleucovorin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea - Vomiting - Mild rash or flushing - Transient hypotension - Mild elevation of liver enzymes - Headache

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis - Acute renal failure - Severe hepatic dysfunction - Life‑threatening hypotension - Neutropenia or severe bone‑marrow suppression - Thromboembolic events

Levoleucovorin requires careful monitoring and appropriate patient selection.

- Renal function monitoring: assess creatinine clearance before and during therapy. - Hepatic function monitoring: check liver enzymes regularly. - Use with caution in patients with known folate metabolism disorders. - Avoid in individuals with documented hypersensitivity to folate analogues. - Pregnancy safety unknown: weigh potential benefits against risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levoleucovorin may interact with other agents affecting folate pathways or renal/hepatic function.

Major Interactions (Avoid): - Concurrent high‑dose methotrexate without proper timing: may reduce rescue effectiveness. - Strong folate antagonists (e.g., pemetrexed) administered simultaneously: can diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal clearance. - Proton pump inhibitors: potential alteration of folate absorption. - Cytotoxic agents that also rely on folate metabolism (e.g., trimetrexate): monitor for additive toxicity.